GlassScriptPhysician profile
Alexander Robert Jack
NPI 1346482627
$4,554.36
in general payments reported to CMS, 2019-2025
23 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $463 · 2021: $447 · 2022: $823 · 2023: $826 · 2024: $697 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.99 |
| Education | $130.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.65 | 2019-2025 | |
| Janssen Biotech, INC. | $686.82 | 2019-2025 | Tremfya |
| Solta Medical, A Division of Bausch Health US, LLC | $508.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $469.12 | 2019-2023 | Dupixent |
| Dermavant Sciences, INC. | $203.52 | 2023-2024 | Vtama |
| Leo Pharma INC. | $185.54 | 2021-2025 | Adbry |
| Journey Medical Corporation | $178.76 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $127.33 | 2020-2025 | Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2023-2024 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $124.45 | 2019-2025 | Aklief |
| Pfizer INC. | $112.07 | 2023-2024 | |
| Incyte Corporation | $106.95 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $104.48 | 2021-2025 | |
| Lilly USA, LLC | $85.66 | 2019-2022 | |
| Ucb, INC. | $85.49 | 2022-2024 | Cimzia, Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $83.70 | 2023-2025 | Zoryve |
| Genzyme Corporation | $66.00 | 2019-2024 | |
| Merz North America, INC. | $46.21 | 2023 | Xeomin |
| Amgen INC. | $38.14 | 2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $31.96 | 2023 | Sotyktu |
| Revance Therapeutics, INC. | $24.43 | 2024 | Daxxify |
| Organon LLC | $18.89 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Jack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.